Earendil Labs Signs Genentech Bispecific Deal Worth Up to $1.5 Billion
Earendil Labs announced a Genentech collaboration on 24 September 2026 to discover bispecific cancer antibodies using generative protein engineering, extending AI biologics deal flow after major enzyme discovery headlines.
What changed
Earendil Labs announced on 24 September 2026 a research collaboration with Genentech, a Roche Group member, to discover and develop multiple therapeutic bispecific antibody programs in oncology. Axios Pro reported the deal value at up to $1.5 billion.
Under the agreement, Earendil will lead antibody discovery and research through early clinical development for pre agreed target combinations. Genentech will take subsequent global clinical development and commercialization. The transaction remains subject to customary closing conditions.
Earendil describes itself as an AI powered biotech combining machine learning, generative protein engineering, and high throughput experiments through its Helixon affiliate. CEO Jian Peng said the partnership pairs Earendil discovery engine with Genentech biologics track record.
Why it matters
AI biologics partnerships are shifting from press release language to named target portfolios with Big Pharma development takeover clauses. For oncology R&D leaders, the structure shows where pharma will pay for early stage generative design while keeping late stage risk in house.
The deal follows Earendil prior large pharma alliances, signaling repeatability rather than a one off platform test.
Who is affected
Biologics discovery teams, computational protein design vendors, oncology BD analysts, and investors comparing AI native biotech pipelines to traditional antibody shops.
What to do next
Benchmark your in house bispecific design cycle against Earendil stated integrated framework for functionality, manufacturability, and developability. If you lack high throughput validation, model partnership economics before building an internal generative stack.
What to watch
Closing announcement, first disclosed target pairs, and whether Genentech moves any program into IND enabling studies within twelve months.
Sources
- Primary. BioSpace, Earendil Labs Announces Research Collaboration with Genentech (24 September 2026). Scope, responsibilities, and closing conditions.
- Secondary. Axios Pro, Earendil and Genentech ink $1.5B cancer deal (24 September 2026). Reported total deal value.